NEWS

NEWS

Total 79

49
Press Release NeoImmuneTech Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting
2021-11-22
48
Press Release NeoImmuneTech Presents Data in Three Posters at Society for Immunotherapy of Cancer Annual Meeting
2021-11-16
47
Press Release NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in combination with PD-L1 checkpoint inhibitor in Frontline Locally Advanced or Metastatic Non-Small Cell Lung Cancer
2021-11-08
46
Press Release NeoImmuneTech Announces First Patient Dosed in Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma
2021-10-13
45
Press Release NeoImmuneTech to Present Three Posters at Society for Immunotherapy of Cancer Annual Meeting
2021-10-05
44
Press Release NeoImmuneTech to Present at Society for Neuro-Oncology Annual Meeting
2021-09-03
43
Press Release NeoImmuneTech Appoints Jean Fan, M.D., as Chief Clinical Officer
2021-08-25
42
Press Release NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection
2021-07-26
41
Press Release NeoImmuneTech Trial Data Presented at American Society of Clinical Oncology Annual Meeting
2021-06-08
40
Press Release NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)
2021-06-08

1 2 3 4 5 >>>